Loading...
XTAE
BOLT
Market cap8mUSD
Jul 14, Last price  
602.10ILS
1D
1.02%
1Q
-3.45%
Jan 2017
-52.76%
IPO
-98.74%
Name

Biolight Life Sciences Ltd

Chart & Performance

D1W1MN
P/E
P/S
12,892.91
EPS
Div Yield, %
Shrs. gr., 5y
0.50%
Rev. gr., 5y
-5.91%
Revenues
219k
+85.59%
52,00082,000941,0001,391,0002,111,0001,209,0003,687,000297,00031,0003,00063,000118,000219,000
Net income
-7m
L-72.55%
-13,356,000-18,837,000-23,102,000-19,259,000-21,824,000-17,260,00065,385,000-12,591,000-13,382,000382,000-7,847,000-26,020,000-7,142,000
CFO
-11m
L+14.80%
-19,460,000-26,225,000-26,987,000-24,037,000-26,942,000-25,318,000-22,390,000-15,357,000-11,395,000-10,026,000-9,540,000-9,577,000-10,994,000

Profile

BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of product candidates include DiagnosTear's TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops; ViSci, an Eye D technology that treats glaucoma by the insertion of a sub conjunctival implant; OphRx that develops drugs for treating eye diseases; and Peripherex, which develops solutions for at-home and in-office diagnosis and monitoring of peripheral vision impairment used by eye care and other providers to diagnose and monitor glaucoma and other diseases. Its pipeline also include AEYE that develops artificial intelligence solutions for a variety of retinal diseases; Tarsier, which develops TRS 01 based on its technological platform for the treatment of Uveitis in patients suffering from high IPO; Belkin Vision that develops clinic fast and automatic laser device to enable glaucoma patients to receive short & effective treatments as treatment to lower IOP; and Sanoculis, which develops an innovative surgical procedure for the treatment of the Glaucoma. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was incorporated in 2005 and is based in Tel Aviv, Israel.
IPO date
Dec 27, 2005
Employees
5
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
219
85.59%
118
87.30%
63
2,000.00%
Cost of revenue
6,472
10,769
6,201
Unusual Expense (Income)
NOPBT
(6,253)
(10,651)
(6,138)
NOPBT Margin
Operating Taxes
(2,449)
Tax Rate
NOPAT
(6,253)
(10,651)
(3,689)
Net income
(7,142)
-72.55%
(26,020)
231.59%
(7,847)
-2,154.19%
Dividends
Dividend yield
Proceeds from repurchase of equity
687
BB yield
-2.67%
Debt
Debt current
533
91
527
Long-term debt
665
91
527
Deferred revenue
1,248
783
Other long-term liabilities
836
Net debt
(22,049)
(27,833)
(47,213)
Cash flow
Cash from operating activities
(10,994)
(9,577)
(9,540)
CAPEX
(28)
(1,415)
(98)
Cash from investing activities
7,553
(1,952)
(10,550)
Cash from financing activities
7,981
3,255
(485)
FCF
(6,415)
(10,206)
(5,145)
Balance
Cash
13,467
8,643
16,379
Long term investments
9,780
19,372
31,888
Excess cash
23,236
28,009
48,264
Stockholders' equity
(234,455)
(220,478)
(196,771)
Invested Capital
267,044
251,706
251,773
ROIC
ROCE
EV
Common stock shares outstanding
4,658
4,644
4,586
Price
5.53
6.39%
5.20
-21.40%
6.61
-42.70%
Market cap
25,753
6.70%
24,136
-20.40%
30,320
-42.70%
EV
7,567
(3,172)
(16,369)
EBITDA
(5,658)
(10,077)
(5,550)
EV/EBITDA
0.31
2.95
Interest
84
66
Interest/NOPBT